Song Ga-in, This Time the Model for DNature Bio Labs Health Functional Foods

- Song Ga-in Secures Position as Brand Model for Brain Healthcare Bio Specialty Company’s Health Functional Foods
- August Launch of Dnature Bio Labs’ Brain Health Product and MOU Signed with Korea Parkinson's Disease Association

DNATURE BIO LABS has selected trot goddess Song Ga-in as the brand model ahead of the launch of its health functional food.

According to DNATURE BIO LABS Co., Ltd., “Song Ga-in’s bright and energetic energy, along with her sincere and thoughtful warm image, which has gained overwhelming support across all age groups through her compelling voice, positively influenced the model selection.”

DNATURE BIO LABS, which has attracted attention following the announcement of Song Ga-in as the model, is a total brain healthcare bio R&D company specializing in the research and development of treatments for neurological diseases.

DNATURE BIO LABS’ ‘Brain Health Functional Food,’ set to launch at the end of August, is a brain health enhancement product designed to improve memory, reduce fatigue, boost immunity, and prevent aging. It is based on Donguibogam and Bonchogangmok, the essence of Oriental medicine, and derives the optimal blend of natural ingredients such as red ginseng, goji berry, cornelian cherry, and polygala root. It can be conveniently consumed anytime and anywhere. After its launch, DNATURE BIO LABS signed a business agreement with the Korea Parkinson’s Disease Association on June 16 to promote welfare and benefits for Parkinson’s disease patients and to pursue practical support.

DNATURE BIO LABS is engaged in the research and development of biopharmaceuticals such as cell therapies for intractable and degenerative neurological diseases including amyotrophic lateral sclerosis (ALS) using neural stem cell platform technology. The company also develops and manufactures health functional foods and operates a functional beverage business. Furthermore, through active acquisition of core technologies and R&D investment, DNATURE BIO LABS is in the process of transferring domestic rights for LMTX®, TauAlX’s new drug, the world’s first tau-based dementia treatment, which is expected to complete global Phase 3 clinical trials next year.